Zacks Investment Research on MSN
Merck indicates better growth visibility in post-Keytruda LOE period
Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...
Stocktwits on MSN
How Merck is preparing for the patent cliff of its blockbuster cancer drug Keytruda
Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...
Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, for all their similarities, have taken markedly different commercial strategies to selling their immuno-oncology drugs. Merck has spent more than ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results